By: IPP Bureau
Last updated : September 28, 2024 3:52 pm
Developed in consultation with clinicians and patients for an enhanced user experience
Baxter International, a leading global medtech company, unveiled its next generation airway clearance system, The Vest Advanced Pulmonary Experience (APX) System, at the North American Cystic Fibrosis Conference.
The Vest APX System supports daily therapy for adults and children with certain chronic lung conditions and retained secretions. The system features the same trusted airflow technology as the previous version, with enhanced comfort and additional patient-centered features driven by clinician and patient input.
“Many patients who are prescribed this therapy use it multiple times a day, every day,” said Jim O’Connell, president of Front Line Care at Baxter. “With that in mind, it was very important for us to design a solution that fits seamlessly into a patient’s daily routine. The Vest APX System offers next-level comfort, ease of use and portability, all while maintaining the performance patients and caregivers have depended on for years.”
Patients with chronic lung conditions such as cystic fibrosis and bronchiectasis can experience mucus blocking the small airways in their lungs. Mucus can trap bacteria, which can lead to lung inflammation and infections.
The Vest APX System uses High Frequency Chest Wall Oscillation (HFCWO) technology to help dislodge mucus from the bronchial walls and mobilize secretions and mucus from the smaller to larger airways where it can be cleared by coughing or suctioning.
Baxter entered the non-invasive respiratory health industry in December 2021 through its acquisition of Hillrom, which has long been a pioneer in airway clearance. Its HFCWO technology has been demonstrated to be a safe and effective airway clearance solution for nearly 200,000 patients over the past 35 years and has been tested in more than 60 clinical studies to date.1